1. Academic Validation
  2. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

  • Bioorg Med Chem Lett. 2020 Oct 1;30(19):127433. doi: 10.1016/j.bmcl.2020.127433.
Neil P Grimster 1 Lakshmaiah Gingipalli 2 Bernard Barlaam 3 Qibin Su 2 XiaoLan Zheng 2 David Watson 3 Haixia Wang 2 Iain Simpson 3 Andy Pike 3 Amber Balazs 2 Scott Boiko 2 Timothy P Ikeda 4 Anna C Impastato 4 Natalie H Jones 4 Sameer Kawatkar 2 Paul Kemmitt 3 Scott Lamont 3 Joe Patel 4 Jon Read 5 Ujjal Sarkar 2 Li Sha 2 Ronald C Tomlinson 4 Haiyun Wang 2 David M Wilson 3 Troy E Zehnder 2 Lianghe Wang 6 Peng Wang 6 Frederick W Goldberg 3 Wenlin Shao 2 Stephen Fawell 2 Hannah Dry 2 James E Dowling 2 Scott D Edmondson 2
Affiliations

Affiliations

  • 1 Oncology R&D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com.
  • 2 Oncology R&D, AstraZeneca, Waltham, USA.
  • 3 Oncology R&D, AstraZeneca, Cambridge, UK.
  • 4 Discovery Sciences, R&D, AstraZeneca, Waltham, USA.
  • 5 Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • 6 Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China.
Abstract

Spleen tyrosine kinase (Syk) is a non-receptor cytosolic kinase. Due to its pivotal role in B cell receptor and Fc-receptor signaling, inhibition of Syk has been targeted in a variety of disease areas. Herein, we report the optimization of a series of potent and selective Syk inhibitors, focusing on improving metabolic stability, pharmacokinetics and hERG inhibition. As a result, we identified 30, which exhibited no hERG activity but unfortunately was poorly absorbed in rats and mice. We also identified a Syk chemical probe, 17, which exhibits excellent potency at Syk, and an adequate rodent PK profile to support in vivo efficacy/PD studies.

Keywords

Bioavailable; SYK; Small molecule.

Figures
Products